A phase I study of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane] platinum(II)in patients with advanced malignancies

Noe Kyeong Kim, Tae You Kim, Sang Goo Shin, Young Iee Park, Jung Ae Lee, Yong Baik Cho, Key H. Kim, Dae Kee Kim, Dae Seog Heo, Yung Jue Bang

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

BACKGROUND. A Phase I study of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-l,3-dioxolane] platinum(II) (SKI 2053R), a new platinum derivative, was performed to determine the maximum tolerated dose (MTD), the dose limiting toxicities (DLTs), and the pharmacokinetic profile of SKI 2053R in patients with advanced, refractory malignancies. METHODS. Twenty-one patients were entered into the study. SKI 2053R was administered with an intravenous infusion over 1 hour every 4 weeks. The SKI 2053R dose was escalated from 40 mg/m2 up to 480 mg/m2 using a modified Fibonacci scheme. Pharmacokinetic analysis was done in all patients to determine the total and ultrafiltrable platinum concentrations in both the plasma and the urine. RESULTS. All patients were evaluable for toxicity and response. There was no significant toxicity with dosages up to 360 mg/m2. At 480 mg/m2, two of three patients developed Grade 4 hepatotoxicity, Grade 3 leukopenia and thrombocytopenia, and Grade 2 azotemia and proteinuria. Other toxicity included nausea and emesis, but it was controlled with antiemetics. SKI 2053R did not cause significant neurotoxicity or mucositis. There were 4 patients with stable disease among the 21 patients. Plasma decay of the total and free platinum concentrations was best fitted by using a two-compartment, open model. The terminal plasma half-life of the total platinum after SKI 2053R administration ranged from 63.4 hours to 114.1 hours in dosages ranging from 40 mg/m2 to 480 mg/m2 without significant dose dependency. However, the terminal plasma half-life of the free platinum concentration showed a significant dose dependent, incremental pattern. The renal excretion of SKI 2053R measured as platinum ranged from 49% to 75% of the administered dose. CONCLUSIONS. The MTD of SKI 2053R was 480 mg/m2. The major DLTs were hepatotoxicity, nephrotoxicity, and myelosuppression. The recommended starting dose for a subsequent Phase II study is 360 mg/m2 once every 4 weeks.

Original languageEnglish
Pages (from-to)1549-1556
Number of pages8
JournalCancer
Volume91
Issue number8
DOIs
StatePublished - 15 Apr 2001

Keywords

  • Dose limiting toxicity
  • Maximum tolerated dose
  • Pharmacokinetics
  • Platinum derivative

Fingerprint

Dive into the research topics of 'A phase I study of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane] platinum(II)in patients with advanced malignancies'. Together they form a unique fingerprint.

Cite this